-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Stomach cancer is the fifth most common cancer in the world and the third most deadly.
patients with a medium survival of less than twelve months and a five-year survival rate of less than 10%.
japan and the United States, about 10% of new gastric cancer cases occur each year with FGFR gene distortion.
Medical Center announced today that it has begun a Phase I/II clinical trial (FIDES-03 study) using the FGFR inhibitor deazantinib.
the multi-queue study was designed to assess the effectiveness and safety of deazantinib's treatment of patients with advanced stomach cancer with FGFR gene abnormalities.
Derazantinib is an oral small molecule FGFR inhibitor with strong activity on FGFR1, 2 and 3.
FGFR kinases are the key drivers of cell proliferation, differentiation and migration.
FGFR genetic distortions, such as gene fusion, mutation or amplification, have been identified as potential therapeutic targets for a variety of cancers, including endovascular, urethra, breast, stomach and lung cancers.
, chief medical officer of Basilea, said: "Preclinical studies have shown that derazantinib has a unique kinase suppression spectrum.
patients with advanced stomach cancer with FGFR genetic abnormalities have very poor prognostics and their medical needs are far from being met."
.
